Patent details

EP3860590 Title: ETRASIMOD FOR USE IN METHODS FOR THE TREATMENT OF SCLERODERMA

Basic Information

Publication number:
EP3860590
PCT Application Number:
US2019054576
Type:
European Patent Granted for LU
Legal Status:
Revoked
Application number:
EP197904048
PCT Publication Number:
WO2020072824
First applicant's nationality:
Translation Language:
EPO Publication Language:
English
English Title of Invention:
ETRASIMOD FOR USE IN METHODS FOR THE TREATMENT OF SCLERODERMA
French Title of Invention:
ETRASIMOD POUR L'UTILISATION DANS LES MÉTHODES POUR LE TRAITMENT DE LA SKLÉRODERMIE
German Title of Invention:
ETRASIMOD ZUR VERWENDUNG IN METHODEN ZUR BEHANDLUNG VON SKLERODERMIE
SPC Number:

Dates

Filing date:
03/10/2019
Grant date:
07/06/2023
EP Publication Date:
11/08/2021
PCT Publication Date:
09/04/2020
Claims Translation Received Date:
Translations Received Date (B1 EP Publication):
Translations Received Date (B2 EP Publication):
Translations Received Date (B3 EP Publication):
Publication date:
07/06/2023
EP B1 Publication Date:
07/06/2023
EP B2 Publication Date:
EP B3 Publication Date:
Lapsed date:
03/10/2023
Expiration date:
03/10/2039
Renunciation date:
Revocation date:
02/10/2024
Annulment date:

Owner

From:
31/05/2023
 
 

Name:
Arena Pharmaceuticals, Inc.
Address:
66 Hudson Boulevard East, New York, NY 10001-2192, United States (US)

Inventor

Name:
ADAMS, John W.
Address:
United States (US)

Priority

Priority Number:
201862740855 P
Priority Date:
03/10/2018
Priority Country:
United States (US)

Classification

IPC classification:
A61K 31/404; A61P 37/00;

Publication

European Patent Bulletin

1

Issue number:
202323
Publication date:
07/06/2023
Description:
Grant (B1)

2

Issue number:
202506
Publication date:
05/02/2025
Description:
Revocation of the European patent

Annual Fees

Annual Fee Due Date:
Annual Fee Number:
Expected Payer:
Last Annual Fee Payment Date:
Last Annual Fee Paid Number:
Payer:
Filing date Document type Number of pages